SHR-1316 Plus Chemotherapy and Sequential Thoracic Radiotherapy as First-line Therapy for Extensive-stage Small-Cell Lung Cancer (ES-SCLC): a Phase II Trial

NCT04562337 Phase 2 ACTIVE_NOT_RECRUITING

This study is a one arm, open, single center phase II study. The main purpose of this study was to evaluate the tolerance and preliminary efficacy of SHR1316 combined with chest radiotherapy after induction therapy.

Details

Lead sponsor	Shandong Cancer Hospital and Institute
Phase	Phase 2
Status	ACTIVE_NOT_RECRUITING
Enrolment	67
Start date	2020-10-01
Completion	2024-10

Conditions

• Extensive-stage Small Cell Lung Cancer

Interventions

• SHR1316
• Carboplatin
• Etoposide
• Radiation therapy
• Cisplatin

Primary outcomes

• overall survival （OS） — Up to approximately 36 months

Countries

China